Guildford, UK, February 11th 2008 – IDBS today announced that the global
biopharmaceutical company UCB has licensed BioBook to be deployed across
multiple European sites for DMPK (Drug Metabolism and Pharmacokinetics) and
pharmacology.
UCB focuses on developing breakthrough treatments for severe diseases within
selected therapeutic areas such as neurological disorders, inflammatory diseases
and oncology. UCB, which transformed into a pure biopharma during 2005, required
a complete solution for managing late stage biological research data. The
decision to invest in BioBook was based on the product’s flexible structure and
its ability to capture complex data in one application, eliminating
transcription errors and providing a better quality of data.
For a high resolution image please contact
nickim@alto-marketing.com
Hector Sanchez, Senior Director R&D Informatics, UCB, commented: “IDBS’
ActivityBase is our company repository primarily for all our screening data.
However, for DMPK and pharmacology we required a solution that would capture
both structured and unstructured data which is why we selected BioBook for these
disciplines. This combination of IDBS products gives us the best of both worlds
and provides a complete view on our data, reducing experiment duplication,
sharing data across the organization and freeing scientists from report
creation, giving them back vital research hours.”
Neil Kipling, founder and CEO of IDBS, commented: “Because of the types of data
captured during DMPK and pharmacology studies, these critical research areas are
often neglected by other informatics providers. Many data management solutions
are not specific or flexible enough to handle this complex data. IDBS recognized
this problem and therefore developed BioBook which provides a tool specifically
designed with the needs of these therapeutic areas in mind.” He added: “BioBook
delivers the benefits of IP protection, workflow support, compliance and
enhanced report generation, as well as offering specific functionality for the
biologist.”
About IDBS:
IDBS is a leading provider of integrated software solutions to the life sciences
industry. Maximising the value of research data by enabling organisations to
capture, store, share and use data efficiently and effectively, whilst
protecting intellectual property across the spectrum of discovery activities.
Headquartered in Guildford, UK, IDBS has U.S. offices in California, New Jersey
and Massachusetts. IDBS partners with CTC Laboratory Systems in Japan and a
network of distributors to market IDBS products and services in Asia. Founded in
1989, IDBS employs more than 150 people worldwide.
About UCB:
UCB, Brussels, Belgium ( www.ucb-group.com
) is a global leader in the biopharmaceutical industry dedicated to the
research, development and commercialization of innovative pharmaceutical and
biotechnology products in the fields of central nervous system disorders,
allergy/respiratory diseases, immune and inflammatory disorders and oncology.
UCB focuses on securing a leading position in severe disease categories.
Employing around 12,000 people in over 40 countries, UCB achieved revenue of 3.5
billion euro in 2006 on a pro forma basis. UCB S.A. is listed on the Euronext
Brussels Exchange and, through its affiliate, owns approx. 89% of the shares of
SCHWARZ PHARMA AG. SCHWARZ PHARMA AG (Monheim, Germany) is a member of the UCB
Group.
11th February 2008 Ref 08IDBS01
Product enquiries
IDBS:
Glyn Williams, VP of Marketing & Product Management:
Tel +44 (0)1483 595010 Email:
gwilliams@idbs.com
Media enquiries
Alto Marketing Limited:
Nicki Muir
Tel +44 (0)1489 557672 Email:
nickim@alto-marketing.com
